This inefficiency could suggest a reduction in antigen presentation capacity due to the loss of B7.1 and B7.2 from antigen-presenting cells, which may impair the activation of anti-tumor CD4 T cells and contribute to the development of an immunosuppressive tumor microenvironment. The gene discussed is CD86; the disease is neoplasm.